HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Held, U. Search for Related Content PubMed PubMed Citation Articles by Held, U. Related Collections Prognosis All Clinical trials Multiple sclerosis

Predictors of relapse rate in MS clinical trials

From Sylvia Lawry Centre for Multiple Sclerosis Research (Dr. Held, L. Heigenhauser, and C. Shang), Munich, Germany; Department of Neurology (Dr. Kappos), University Hospital, Basel, Switzerland; and Department of Neurology (Dr. Polman), Vrije Universiteit Medical Center, Amsterdam, The Netherlands.

Address correspondence and reprint requests to Prof. Dr. Chris Polman, VU Medical Centre Amsterdam, PO Box 7057, 1007 MB Amsterdam, The Netherlands; e-mail: ch.polman{at}vumc.nl

Background: The annual relapse rate has been commonly used as a primary efficacy endpoint in phase III multiple sclerosis (MS) clinical trials. The aim of this study was to determine the relative contribution of different possible prognostic factors available at baseline to the on-study relapse rate in MS.

Methods: A total of 821 patients from the placebo arms of the Sylvia Lawry Centre for Multiple Sclerosis Research (SLCMSR) database were available for this analysis. The univariate relationships between on-study relapse rate and the baseline demographic, clinical, and MRI-based predictors were assessed. The multiple relationships were then examined using a Poisson regression model. Two predictor subsets were selected. Subset 1 included age at disease onset, disease duration, sex, Expanded Disability Status Scale (EDSS) at baseline, number of relapses in the last 24 months prior to baseline, and the disease course (relapsing remitting [RR] and secondary progressive [SP]). Subset 2 consisted of Subset 1 plus gadolinium enhancement status in MRI. The number of patients for developing the models with no missing values was 727 for Subset 1 and 306 for Subset 2.

Results: The univariate relationships show that the on-study relapse rate was higher for younger and for female patients, for RR patients than for SP patients, and for patients with positive enhancement status at entry (Wilcoxon test, p < 0.05). A higher on-study relapse rate was associated with a shorter disease duration, lower entry EDSS, more pre-study relapses, and more enhancing lesions in T1 at entry. The fitted Poisson model shows that disease duration (estimate = –0.02) and previous relapse number (estimate = 0.59 for one, 0.91 for two, and 1.45 for three or more relapses vs no relapses) remain. The authors were able to confirm these findings in a second, independent dataset.

Conclusions: The relapse number prior to entry into clinical trials together with disease duration are the best predictors for the on-study relapse rate. Disease course did not contribute independently because its effect is covered by the pre-study relapse rate. Gadolinium enhancement status, given the other covariates, has no significant influence on the on-study relapse rate.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the December 13 issue to find the title link for this article.

*These authors contributed equally.

L.K. is supported by the Swiss Multiple Sclerosis Society. L.H. is funded by SFB 386 of the German Research Foundation.

Disclosure: The authors report no conflicts of interest.

Received April 19, 2005. Accepted in final form August 22, 2005.

This article has been cited by other articles:

				M. Daumer, A. Neuhaus, S. Morrissey, R. Hintzen, and G. C. Ebers MRI as an outcome in multiple sclerosis clinical trials Neurology, February 24, 2009; 72(8): 705 - 711. [Abstract] [Full Text] [PDF]

				M. P. Gorman, B. C. Healy, M. Polgar-Turcsanyi, and T. Chitnis Increased Relapse Rate in Pediatric-Onset Compared With Adult-Onset Multiple Sclerosis Arch Neurol, January 1, 2009; 66(1): 54 - 59. [Abstract] [Full Text] [PDF]

				J Petkau, S. Reingold, U Held, G. Cutter, T. Fleming, M. Hughes, D. Miller, H. McFarland, and J. Wolinsky Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses Multiple Sclerosis, July 1, 2008; 14(6): 770 - 778. [Abstract] [PDF]

				M Koch, M Uyttenboogaart, A van Harten, and J De Keyser Factors associated with the risk of secondary progression in multiple sclerosis Multiple Sclerosis, July 1, 2008; 14(6): 799 - 803. [Abstract] [PDF]

				M. P. Sormani, M. Rovaris, G. Comi, and M. Filippi A composite score to predict short-term disease activity in patients with relapsing-remitting MS Neurology, September 18, 2007; 69(12): 1230 - 1235. [Abstract] [Full Text] [PDF]

				Y. Kinoshita, T. Uo, S. Jayadev, G. A. Garden, T. P. Conrads, T. D. Veenstra, and R. S. Morrison Potential Applications and Limitations of Proteomics in the Study of Neurological Disease Arch Neurol, December 1, 2006; 63(12): 1692 - 1696. [Full Text] [PDF]